After coming short of declaring a clinically meaningful benefit for Trodelvy in stalling cancer progression or death in patients with pretreated HR-positive, HER2-negative breast cancer, Gilead is probably focusing on a final analysis of gold-standard patient survival data, RBC Capital Markets analyst Brian Abrahams said in a Tuesday note after speaking with Gilead’s investor relations team. That analysis is due in 2024.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,